Company profile
GENPREX, INC.
NASDAQ:GNPXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| QUARATUSUGENE OZEPLASMID | phase1_2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05703971 | phase1_2 | recruiting | 2024-05-09 | 2027-12-01 | Genprex, Inc. | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients |
| NCT04486833 | phase1_2 | recruiting | 2021-09-03 | 2028-03-01 | Genprex, Inc. | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib |
| NCT05062980 | phase1 | terminated | 2022-03-30 | 2025-02-03 | Genprex, Inc. | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer |
| NCT01455389 | phase1_2 | terminated | 2014-02-01 | 2016-10-27 | Genprex, Inc. | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer |
FDA applications (0)
No records yet.